DR. Reddy’s Laboratories Limited RDY
Annual
Quarterly
FY2025 · ended Mar 31, 2025 · Revenue $3.81B, +13.8% YoY · Filed Jun 6, 2025
DR. Reddy’s Laboratories Limited (RDY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Mar 31, 2025, it reported revenue of $3.8 billion and net income of $671.0 million. Free cash flow was $223.0 million. As of Mar 31, 2025 it held $172.0 million in cash and investments and $547.0 million in total debt.
Revenue
$3.81B
+13.8% vs prior year
Net income
$671.00M
+0.4% vs prior year
Operating cash flow
$545.00M
+0.0% vs prior year
Free cash flow
$223.00M
-35.9% vs prior year
EPS
$0.79
-80.3% vs prior year
Dividend per share
None
Shares outstanding
834.66M
+0.0% vs prior year
Net cash
$-375.00M
FY 2025
Operating margin
22.1%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RDY (NYSE)
- Fiscal year ends
- March 31
- Incorporated in
- India
- Headquarters
- Hyderabad
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1135951
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
FY 2021 Mar 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.4B | $3.0B | $2.8B | $2.6B |
| Operating income | $842.0M | $813.0M | $695.0M | $389.0M | $332.0M |
| Net income | $671.0M | $668.0M | $548.0M | $311.0M | $236.0M |
| Diluted EPS | $0.79 | $4.01 | $3.30 | $1.87 | $1.52 |
| Operating cash flow | $545.0M | $545.0M | $716.0M | $370.0M | $488.0M |
| Free cash flow | $223.0M | $348.0M | $578.0M | $177.0M | $355.0M |
| Total assets | $5.8B | $4.7B | $3.9B | $3.9B | $3.6B |
| Total liabilities | $1.8B | $1.3B | $1.1B | $1.3B | $1.3B |
| Stockholders' equity | $3.9B | $3.4B | $2.8B | $2.5B | $2.4B |
| Cash and investments | $172.0M | $85.0M | $70.0M | $196.0M | $203.0M |
| Total debt | $547.0M | $241.0M | $164.0M | $446.0M | $414.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 5, 2026 | Nov 5, 2026 |
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 4, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 28, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 24, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 24, 2026 |
All 1002 DR. Reddy’s Laboratories Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.